Real-World Outcomes in HER2-Positive NSCLC

Key Takeaways

• Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment settings.
• Clinical trials involve selected patients, while real-world settings include those with comorbidities and varying performance statuses.
• Common adverse events with HER2-directed therapies include diarrhea, fatigue, and cardiac dysfunction.
• Management of adverse events involves dose adjustments, supportive care, and close monitoring to optimize treatment strategies.